| Document |
Document Title |
|
JP3253181B2 |
PURPOSE: To obtain a photochemical labeling reagent useful for genetic phatogonomy by adding a digoxigenin derivative, a spacer molecule, and a furocoumarin derivative to the reagent. CONSTITUTION: A labeling reagent expressed by a formu...
|
|
JP2002030063A |
To provide a method for producing a sulfamate compound, which can be applied to various hydroxyl group-containing compounds having various functional groups and by which the sulfamate compound can be produced from necessary minimal amoun...
|
|
JP2002502406A |
This invention describes 11beta-aryl-substituted 14,17-ethanoestratrienes of general formula (I). The new compounds are selective estrogens whose action occurs in a tissue-selective manner. The estrogenic action occurs in particular on b...
|
|
JP2001527089A |
New estrone sulfamate derivatives (I), their salts and esters are useful for treating estrogen-dependent disorders, particularly breast cancer in post-menopausal women. Compounds (I), their salts and esters are new: r : single or double ...
|
|
JP2001527088A |
This invention describes the new 11beta-halogen-7alpha-substituted estratrienes of general formula Iin whichR<11 >is a fluorine or chlorine atom, and the other substituents have the meanings that are explained in more detail in the descr...
|
|
JP2001354590A |
To provide a medicine for combination therapy of benign prostatic hyperplasia, capable of reducing undesirable side effects.A medicine for the prophylaxis and/or treatment of benign prostatic hyperplasia is provided. The medicine compris...
|
|
JP2001526233A |
Compositions of angiostatic agents for treating GLC1A glaucoma and methods for their use are disclosed.
|
|
JP2001526673A |
The invention relates to 20-aralkyl-5alpha-pregnane derivative having general formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 is (H,OR), (H,OSO3H) or NOR; R is H, (C1-6)alkyl or (C1-6)acyl; each of R2 and R3 is ind...
|
|
JP2001525855A |
Novel and anti-estrogenic compounds are provided which are useful to treat a variety of disorders, particularly estrogen-dependant disorders. Preferred compounds have 1,3,5-estratiene nucleus, and are substituted at the C-17 or C-11 posi...
|
|
JP3237882B2 |
PURPOSE: To prepare a bile acid derivative having high affinity for the specified bile acid transport system of the small intestine, inhibiting bile acid absorption in a concentration-dependent and competitive manner and effective for th...
|
|
JP2001524525A5 |
|
|
JP2001524525A |
A sulphamate compound suitable for use as an inhibitor of oestrone sulphatase (E.C.3.1.6.2) is described. The compound is a polycyclic compound comprising at least two ring components, wherein the polycyclic compound comprises at least o...
|
|
JP3231901B2 |
PURPOSE: To obtain the subject compd. having progestational activity and antiesterogenic activity by a new method using a specified compd. as the starting material. CONSTITUTION: First, a compd. expressed by formula I (R1 is a 1-3C alkyl...
|
|
JP2001523219A |
Process for preparing steroids having a carboxamide side-chain of formula (I) wherein: the formula - - - are each independently, single or double bonds; z is a single bond, or a straight or branched C1-C5 alkylene; the moiety represents ...
|
|
JP3226919B2 |
The present invention concerns steroidic 5 alpha -reductase inhibitors having the following formula (I) wherein Y is oxygen or sulphur; R is a group: a) -OR4, wherein R4 is hydrogen or a C1-C6 alkyl group; b) wherein each of R5 and R6, i...
|
|
JP2001520235A |
The invention provides estrogens and antiestrogens of formula (I) having structure (I) wherein R is (II), (III), (IV), or (V); R<1> and R<2> are each, independently, alkyl of 1-6 carbon atoms, or are alkyl groups which are taken together...
|
|
JP2001519366A |
The invention relates to the use of arsenic trioxide to treat a solid tumor selected from the group consisting of breast, colon, ovarian, renal, bladder, prostate and lung cancer.
|
|
JP2001519438A |
Bile acid metal salts of therapeutic interest and pharmaceutical and veterinary composition containing same for the treatment of anemias and other conditions are described.
|
|
JP3219408B2 |
The present invention provides a pharmaceutical composition comprising a compound admixed with a pharmaceutically acceptable diluent or carrier; wherein the compound has the the formula wherein each of R1 and R2 is independently selected...
|
|
JP2001517678A |
The invention concerns dietary fat compositions that contain the hydroxy acid or dicarboxylic acid or amino acid esters of a phytosterol and/or phytostanol, or the mixed esters formed with the alcohols, polyols or polyol (C2 . . . C22)-f...
|
|
JP2001517682A |
A new gene in the G-coupled protein receptor family is discribed that is induced by IL-9, thereby providing a therapeutic target in IL-9 mediated development of atopic allergy, asthma-related disorders and certain lymphomas or leukemias....
|
|
JP2001515518A |
PCT No. PCT/EP98/08527 Sec. 371 Date Aug. 27, 1999 Sec. 102(e) Date Aug. 27, 1999 PCT Filed Dec. 17, 1998 PCT Pub. No. WO99/35161 PCT Pub. Date Jul. 15, 1999A process for producing a compound of formula (I): wherein the dotted lines - - ...
|
|
JP3202240B2 |
The present invention relates to a process for the preparation and manufacture of 3-amino-substituted glycosylated bile acid derivatives. Novel intermediates and related compounds are also disclosed.
|
|
JP3202224B2 |
New 11 beta -aryl-gona-4,9-dienes of general formula (I), in which R<1>, R<2>, R<3>, R<4> and R<5> have the meaning given in the derscription, possess a marked antigestagenic activity and are suitable for the manufacture of drugs.
|
|
JP2001510200A5 |
|
|
JP2001510200A |
Sulfatase inhibitor compounds having the formula: ined in the specification. The compounds are useful in the treatment of estrogen dependent illnesses. Methods for synthesizing these compounds are also disclosed.
|
|
JP2001510170A |
Methods for treating ocular neovascularization using photodynamic therapy in combination with an angiostatic steriod are disclosed.
|
|
JP2001509792A |
Multiple novel reaction schemes, novel process steps and novel intermediates are provided for the synthesis of epoxymexrenone and other compounds of Formula Iwherein-A-A- represents the group -CHR4-CHR5- or -CR4=CR5-;R3, R4 and R5 are in...
|
|
JP3181589B2 |
PCT No. PCT/EP91/02493 Sec. 371 Date Oct. 27, 1993 Sec. 102(e) Date Oct. 27, 1993 PCT Filed Dec. 21, 1991 PCT Pub. No. WO92/11277 PCT Pub. Date Jul. 9, 1992Compounds of the general formula I (I) are described, in which x represents an ox...
|
|
JP2001508079A |
PCT No. PCT/EP98/00377 Sec. 371 Date Jul. 14, 1999 Sec. 102(e) Date Jul. 14, 1999 PCT Filed Jan. 13, 1998 PCT Pub. No. WO98/31702 PCT Pub. Date Jul. 23, 1998The present invention relates to certain 16-hydroxy-11-(substituted phenyl)-estr...
|
|
JP2001506267A |
An aminosterol compound according to the following formula: wherein: R1 is a member selected from the group of: R2 is H or OH; R3 is H or OH; R4 is H or OH; and R5 is a C1 to C12 alkyl group. Preferably, R5 is a C1 to C6 alkyl group, and...
|
|
JP2001505221A |
A compound is described. The compound is suitable for use as an inhibitor of oestrone sulphatase. The compound has the Formula I; wherein A is a first group; B is an aryl ring structure having at least 4 carbon atoms in the ring and wher...
|
|
JP2001503732A |
Steroid compounds having various oxygen substitution on the steroid nucleus are disclosed. A specific functionality present on many of the steroid compounds is oxygen substitution at both of positions 6 and 7. Thus, certain steroids have...
|
|
JP2001503024A |
The present invention describes new substituted 7T-(--aminoalkyl)-estratrienes of general formula (I), in which the side chain SK is a radical of partial formula (II), where m equals 4, 5 or 6; n equals 0, 1 or 2; x equals 0, 1 or 2; A i...
|
|
JP2000516209A |
Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or ac...
|
|
JP3115282B2 |
To obtain a new lipid compound capable of recovering the flexibility of skins, and the gloss and pliability of hairs, and useful for cosmetics, etc. This compound corresponds to a compound corresponding to formula I (R1 is a 1-31C, prefe...
|
|
JP2000515861A |
This invention relates to the synthesis of novel cationic, amphiphilic lipids and their application as gene transfer vehicles in vitro and in vivo. For this a series of different lipids (diglycerides, steroids) were synthesized by modifi...
|
|
JP2000515138A |
Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. By this invention, such cationic amphiphile is used in a state in which it is capable of accepting additional pr...
|
|
JP2000309599A |
To obtain a new compound exhibiting steroid sulfatase inhibitory activity and useful for the therapy or prophylaxis for hormone dependent diseases. This compound is represented by formula I (R1 is OH, an alkoxy or group NR2R3; R2 are eac...
|
|
JP2000309536A |
To obtain the subject composition useful for treating prostatic adenocarcinoma by including a specific steroid 5-α-reductase inhibiting compound and a carrier. This pharmaceutical composition is obtained by including (A) a steroid 5-α-...
|
|
JP2000256390A |
To obtain a medicine composition useful for treating diseases related to estrogen and androgen by making the composition include a pharmacologically acceptable diluent, or the like, and a specific sex steroid activity inhibitor. This com...
|
|
JP3073803B2 |
The invention relates to the compounds: either n = 1, K = oxygen, R17 = hydroxyl, R'17 = hydrogen, ethynyl, RA = methyl, RA' = isopropyl, butyl, heptafluorobutyl, X = methylene, phenylene or phenyloxy, Y = -(CH2)7; -(CH2)8-; -(CH2)5-C ID...
|
|
JP2000509072A |
The present invention relates to a pharmaceutical composition or preparation which comprises hydroxyl containing steroidal hormones and organic nitrite/nitrate or other nitric oxide donating agents.
|
|
JP3065109B2 |
Products of formula (I): in which: R = H, alkyl, alkenyl, alkynyl, haloalkyl or alkylthio, (-> 6c) or arylthio, aryl, acyl (-> 12c) or CN (CH2)m-Rc in which Rc denotes OH, SH or Salk (1 to 6c), cycloalk (3 to 6c), m = 1, 2 or 3, X = O N-...
|
|
JP2000508333A |
The subject of the invention is the products of formula (I):in which either R1 represents halogen, hydroxyl, (C1-C8) alkyloxy or (C1-C12) acyloxy, and R2 represents halogen or hydrogen, or R1 and R2 form together a double bond, Z is chos...
|
|
JP3058710B2 |
The present invention is directed to a group of compounds which are haloethyl substituted steroidal enzyme inhibitors. These compounds are useful as aromatase, 19-hydroxylase, and aldosterone biosynthesis inhibitors.
|
|
JP3056770B2 |
Products of general formula (I): in which R1 denotes an aliphatic hydrocarbon radical, R2 and R3, which are identical or different, denote a hydrogen atom or an alkyl radical, G denotes a hydrocarbon group containing from one to eighteen...
|
|
JP2000506889A |
The present invention is a process of converting a hydroxy aromatic into a 2-hydroxy-N-arylacetamide, comprising: (1) treating a reaction mixture comprising a salt of a hydroxy aromatic with an alkylating agent; and (2) treating the reac...
|
|
JP3049504B2 |
Angiostatic steroids for use in controlling ocular hypertension are disclosed. Pharmaceutical compositions of the angiostatlc steroids and their use in treating ocular hypertension, including controlling the ocular hypertension associate...
|
|
JP3048636B2 |
PCT No. PCT/EP91/02494 Sec. 371 Date Jun. 22, 1993 Sec. 102(e) Date Nov. 1, 1993 PCT Filed Dec. 21, 1991 PCT Pub. No. WO92/11278 PCT Pub. Date Jul. 9, 1992.Novel compounds of the general formula I (I) and the pharmacologically tolerable ...
|
